Clinical Trials Browser

Phase 2 × Neoplasms, Mesothelial × defactinib × Clear all

NCT02004028 2024-02-20

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Phase 2 Terminated

35 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Adenoma, Mesothelioma, Neoplasms, Mesothelial